医师-药师协作模式在静脉血栓栓塞症患者治疗中的临床研究

Clinical research of physician-pharmacist collaboration pattern in treatment of venous thrombus embolism patients

目的研究医师-药师协作模式对静脉血栓栓塞症(VTE)患者治疗的影响。方法 90例急性VTE患者依据入院时间先后顺序分为对照组与观察组,各45例。两组患者均采用华法林治疗,对照组采用常规治疗管理方法 ,观察组在对照组基础上采用医师-药师协作模式对患者进行治疗管理,观察比较两组患者治疗效果。结果观察组住院时间及VTE复发、发生出血事件、出院后按时复诊、出院后国际标准化比值(INR)达标率分别为(8.1±5.1)d、0、0、91.1%、84.4%,对照组住院时间及VTE复发、发生出血事件、出院后按时复诊、出院后INR达标率分别为(10.8±5.9)d、11.1%、8.9%、71.1%、48.9%,两组比较差异具有统计学意义(P<0.05)。治疗结束3个月后对全部患者进行影像学复查发现,观察组阴性率为88.9%(40/45),对照组阴性率为46.7%(21/45),差异具有统计学意义(P<0.05)。结论对VTE患者的管理采用医师-药师协作管理模式,能够有效提高治疗效果,改善服用华法林的患者INR达标情况,减少复发,降低出血的风险。

Objective To research influence by physician-pharmacist collaboration pattern on treatment of venous thrombus embolism（VTE） patients. Methods A total of 90 patients with acute VTE were divided by admission order into control group and observation group, with 45 cases in each group. Both groups received warfarin for treatment, and the control group received conventional treatment management measures, while the observation group also received additional physician- pharmacist collaboration pattern for treatment management. Curative effects were observed and compared between the two groups. Results The observation group had hospital stay time, recurrent VTE, bleeding event, regular reexamination, standard rate of international normalized ratio（INR） respectively as（8.1±5.1） d, 0, 0, 91.1% and 84.4%. The control group had hospital stay time, recurrent VTE, bleeding event, regular reexamination, standard rate of INR respectively as（10.8±5.9）d, 11.1%, 8.9%, 71.1% and 48.9%. The difference between the two groups had statistical significance（P〈0.05）. In 3 months after treatment, imaging reexamination showed negative rate as 88.9%（40/45） in the observation group and 46.7%（21/45） in the control group. Their difference had statistical significance（P〈0.05）. Conclusion Implement of physician- pharmacist collaboration pattern for VTE patients can effectively enhance curative effect, improve standard rate of INR in patients receiving warfarin, reduce recurrence, and decrease risk of bleeding.